Domperidone is a dopamine D2-receptor antagonist with peripheral gastrointestinal and endocrine effects. Its most established veterinary role is prevention or treatment of fescue-associated reproductive dysfunction and agalactia in mares. Additional uses include selected lactation-support protocols and, in some markets, immunomodulatory management related to canine leishmaniosis.
Group
Dopamine antagonist
Mechanism of Action
Domperidone blocks dopamine D2 receptors with relatively limited penetration into the brain. At pituitary lactotrophs, removal of dopamine-mediated inhibition increases prolactin secretion and can support mammary development and milk production. Peripheral dopamine antagonism can alter upper gastrointestinal motility. Prolactin-associated modulation of cellular immunity is proposed to contribute to its use in canine leishmaniosis.
Dose Rates
Dog
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Gastroparesis adjunct | 2–5 mg/animal | PO | Every 8–12 h | |
| Leishmaniasis adjunct | 1 mg/kg | PO | Every 12 h | Up to 30 days |
| Lactation support | 2.2 mg/kg | PO | Up to 21 days; During nursing for 1–3 weeks; dosing frequency not specified. | |
| Prokinetic therapy | 0.05–0.1 mg/kg | PO | Every 12–24 h | Suggested from experimental data; limited clinical experience. |
| Gastritis-associated vomiting | 2–5 mg | PO | Every 8–12 h |
Cat
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Gastroparesis adjunct | 2 mg/animal | PO | Every 8–12 h | |
| Lactation support | 1.5–2 mg/kg | PO | Up to 21 days; During nursing for 1–3 weeks; dosing frequency not specified. | |
| Prokinetic therapy | 0.05–0.1 mg/kg | PO | Every 12–24 h | Suggested from experimental data; limited clinical experience. |
Horse
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Fescue toxicosis or agalactia | 1.1 mg/kg | PO | Every 24 h | Start 10 days before expected foaling; continue through foaling and for up to 5 additional days if milk remains inadequate. |
| Laminitis adjunct | 1.1 mg/kg | PO | Clinical efficacy not established. | |
| PPID diagnostic challenge | 5 mg/kg | PO | Once | Measure endogenous ACTH at baseline, 2 and 4 hours; interpret using the laboratory protocol. |
Indications
- Prevention or treatment of fescue-toxicosis-associated agalactia and related periparturient reproductive dysfunction in mares.
- Induction or support of lactation in selected mares within a reproductive management protocol.
- Extra-label support of milk production in selected lactating dogs or cats; veterinary efficacy evidence is limited.
- Adjunctive management of selected gastrointestinal hypomotility or gastroparesis, with limited species-specific clinical evidence.
- Immunomodulatory management or risk reduction of canine leishmaniosis where included in a locally authorized program; evidence and patient selection are indication-specific.
Contraindications
- Gastrointestinal obstruction
Interactions
- Antacids and acid-suppressing drugs may impair oral absorption.
Adverse effects
- Endocrine changes including increased prolactin and ACTH
- Potential cardiac rhythm concerns
Preparations
| Preparation | Form | Strength | Route |
|---|---|---|---|
| Domperidone 10 mg | Tablet | 10 mg / tablet | PO |
| Equidone oral gel 110 mg/mL | Oral Gel | 110 mg / mL | PO |
Monitoring and Administration
Assess milk production and gastrointestinal response. Equine oral prokinetic efficacy and clinical benefit in laminitis are uncertain.
Experimental equine IV 0.2 mg/kg improved motility, but no commercial IV formulation is supplied.